Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk

Vicki Fung, Ilana Graetz, Mary Reed, Marc G Jaffe, Vicki Fung, Ilana Graetz, Mary Reed, Marc G Jaffe

Abstract

Background: Patient reports of their adherence behaviors, concerns about statins, and perceptions of atherosclerotic cardiovascular disease (ASCVD) risk could inform approaches for improving adherence to statin therapy. We examined these factors and their associations with adherence.

Methods: We conducted telephone interviews among a stratified random sample of adults receiving statins within an integrated delivery system (N = 730, 81% response rate) in 2010. We sampled equal numbers of individuals in three clinical risk categories: those with 1) coronary artery disease; 2) diabetes or other ASCVD diagnosis; and 3) no diabetes or ASCVD diagnoses. We assessed 15 potential concerns about and barriers to taking statins, and perceived risk of having a heart attack in the next 10 years (0-10 scale). We calculated the proportion of days covered (PDC) by statins in the last 12 months using dispensing data and used multivariate logistic regression to examine the characteristics associated with non-adherence (PDC<80%). Analyses were weighted for sampling proportions.

Results: Sixty-one percent of patients with PDC<50% reported not filling a new prescription, splitting or skipping statins, or stopping refilling statins in the last 12 months vs. 15% of those with PDC≥80% (p<0.05). The most commonly reported concerns about statins were preferring to lower cholesterol with lifestyle changes (66%), disliking medications in general (59%), and liver or kidney problems (31%); having trouble remembering to take statins (9%) was the most common reason for taking less than prescribed. In multivariate analyses, clinical risk categories were not significantly associated with odds of non-adherence; however, those with higher perceived risk of heart attack were less likely to be non-adherent.

Conclusions: Patient-reported medication-taking behaviors were correlated with statin PDC and those with lower perceived cardiovascular risk were less likely to be adherent. These findings highlight the importance of eliciting from and educating patients on their adherence behaviors and ASCVD risks.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Patients’ perceived risk of heart…
Fig 1. Patients’ perceived risk of heart attack in the next 10 years by clinical risk category.
Note: Based on patients’ rating of their perceived risk of heart attack in next 10 years: 0 (absolutely no chance) to 10 (absolutely sure to happen). Weighted for sampling proportions.
Fig 2. Percent of patients reporting statin…
Fig 2. Percent of patients reporting statin non-adherence behaviors in the last 12 months by statin PDC level.
Note: Weighted for sampling proportions; *p

Fig 3. Percent of patients reporting concerns…

Fig 3. Percent of patients reporting concerns about statins and whether they took fewer statins…

Fig 3. Percent of patients reporting concerns about statins and whether they took fewer statins because of the concern.
Weighted for sampling proportions.
Fig 3. Percent of patients reporting concerns…
Fig 3. Percent of patients reporting concerns about statins and whether they took fewer statins because of the concern.
Weighted for sampling proportions.

References

    1. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation. 2013.
    1. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2014;129:S49–S73. doi:
    1. Pencina MJ, Navar-Boggan AM, D'Agostino RB, Williams K, Neely B, Sniderman AD, et al. Application of New Cholesterol Guidelines to a Population-Based Sample. New England Journal of Medicine. 2014;370(15):1422–31. doi:
    1. Bermingham M, Hayden J, Dawkins I, Miwa S, Gibson D, McDonald K, et al. Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. Clin Ther. 2011;33(9):1180–9. Epub 2011/08/16. doi: .
    1. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196–202. Epub 2009/11/06. doi: .
    1. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. Jama. 2002;288(4):455–61. Epub 2002/07/23. .
    1. Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011;107(11):1662–6. Epub 2011/03/29. doi: .
    1. Vicki F, Sinclair F, Wang H, Dailey D, Hsu J, Shaber R. Patients' Perspectives on Nonadherence to Statin Therapy: A Focus-Group Study. The Permanente journal. 2010;14(1):4–10.
    1. Maningat P, Gordon BR, Breslow JL. How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy? Current atherosclerosis reports. 2013;15(1):291-. doi:
    1. Ho PM, Lambert-Kerzner A, Carey EP, Fahdi IE, Bryson CL, Melnyk SD, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med. 2014;174(2):186–93. Epub 2013/11/20. doi: .
    1. Calvert SB, Kramer JM, Anstrom KJ, Kaltenbach LA, Stafford JA, Allen LaPointe NM. Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J. 2012;163(4):657–65 e1. Epub 2012/04/24. doi: .
    1. Rash JA, Campbell DJ, Tonelli M, Campbell TS. A systematic review of interventions to improve adherence to statin medication: What do we know about what works? Prev Med. 2016;90:155–69. Epub 2016/07/15. doi: .
    1. Lewey J, Shrank WH, Avorn J, Liu J, Choudhry NK. Medication adherence and healthcare disparities: impact of statin co-payment reduction. Am J Manag Care. 2015;21(10):696–704. Epub 2015/12/04. .
    1. Haskard Zolnierek KB, DiMatteo MR. Physician Communication and Patient Adherence to Treatment: A Meta-analysis. Medical care. 2009;47(8):826–34. doi:
    1. Kuntz JL, Safford MM, Singh JA, Phansalkar S, Slight SP, Her QL, et al. Patient-centered interventions to improve medication management and adherence: a qualitative review of research findings. Patient Educ Couns. 2014;97(3):310–26. Epub 2014/09/30. doi: .
    1. Fung V, Reed M, Price M, Brand R, Dow WH, Newhouse JP, et al. Responses to Medicare drug costs among near-poor versus subsidized beneficiaries. Health Serv Res. 2013;48(5):1653–68. Epub 2013/05/15. doi: .
    1. Hsu J, Fung V, Price M, Huang J, Brand R, Hui R, et al. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. Jama. 2008;299(16):1929–36. Epub 2008/04/24. doi: .
    1. Reed M, Brand R, Newhouse JP, Selby JV, Hsu J. Coping with prescription drug cost sharing: knowledge, adherence, and financial burden. Health Serv Res. 2008;43(2):785–97. Epub 2008/03/29. doi: .
    1. Madden JM, Graves AJ, Ross-Degnan D, Briesacher BA, Soumerai SB. Cost-related medication nonadherence after implementation of Medicare Part D, 2006–2007. Jama. 2009;302(16):1755–6. Epub 2009/10/29. doi: .
    1. Madden JM, Graves AJ, Zhang F, Adams AS, Briesacher BA, Ross-Degnan D, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. Jama. 2008;299(16):1922–8. Epub 2008/04/24. doi: .
    1. Patel MJ, de Lemos JA, Philips B, Murphy SA, Vaeth PC, McGuire DK, et al. Implications of family history of myocardial infarction in young women. Am Heart J. 2007;154(3):454–60. Epub 2007/08/28. doi: .
    1. Petr EJ, Ayers C, Pandey A, de Lemos J, Powell-Wiley TM, Khera A, et al. Perceived Lifetime Risk for Cardiovascular Disease (From the Dallas Heart Study). The American journal of cardiology. 2014;114(1):53–8. doi:
    1. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004;42(7):649–52. Epub 2004/06/24. .
    1. Misono AS, Cutrona SL, Choudhry NK, Fischer MA, Stedman MR, Liberman JN, et al. Healthcare information technology interventions to improve cardiovascular and diabetes medication adherence. Am J Manag Care. 2010;16(12 Suppl HIT):SP82–92. Epub 2011/02/16. .
    1. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167(6):540–50. Epub 2007/03/29. doi: .
    1. Nair KV, Belletti DA, Doyle JJ, Allen RR, McQueen RB, Saseen JJ, et al. Understanding barriers to medication adherence in the hypertensive population by evaluating responses to a telephone survey. Patient Prefer Adherence. 2011;5:195–206. Epub 2011/05/17. doi: .
    1. Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–22. Epub 2011/05/11. .
    1. Martin SS, Sperling LS, Blaha MJ, Wilson PWF, Gluckman TJ, Blumenthal RS, et al. Clinician-Patient Risk Discussion for Atherosclerotic Cardiovascular Disease Prevention: Importance to Implementation of the 2013 ACC/AHA Guidelines. Journal of the American College of Cardiology. 2015;65(13):1361–8. doi:
    1. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224–32. Epub 2003/12/06. doi: .
    1. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332–7. Epub 2006/02/16. doi: .
    1. Karter AJ, Parker MM, Solomon MD, Lyles CR, Adams AS, Moffet HH, et al. Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE). Health Serv Res. 2017. Epub 2017/05/06. doi: .
    1. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr., Garcia FA, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. Jama. 2016;316(19):1997–2007. Epub 2016/11/14. doi: .
    1. Ye X, Gross CR, Schommer J, Cline R, St Peter WL. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther. 2007;29(12):2748–57. Epub 2008/01/19. doi: .

Source: PubMed

3
Se inscrever